The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design

Journal article : Review

The presence of hormonal receptors in meningiomas has been known for decades. More recently, evidence has shown increased prevalence of meningiomas in patients taking certain types of hormonal treatments, such as oral contraceptives, progestins or hormone replacement therapy. Epidemiological evidence suggests that patients undergoing hormonal therapy harbor higher mutational rates of the oncogene PIK3CA. Due to the relative paucity of literature describing the intersection of hormone therapy and mutated PIK3CA pathways in meningioma, we have conducted a narrative review on this topic. Similarly, the clinical trial landscape for hormonal therapies for meningioma currently focuses on somatostatin receptor-targeted therapies and peptide receptor radionucleotide therapy, and the PIK3CA-hormonal signaling axis has not been explicitly targeted. Given the role of PIK3CA mutations in promoting cancer progression in other hormone-sensitive tumors, such as breast and prostate cancer, exploring this axis could inform drug repurposing including hormonal therapy specifically for these tumors.

Authors: Abikenari, M; Regev, A; Himic, V; Choi, J; Jeyaretna, S

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Journal of Neuro-Oncology
• Volume: 174
• Issue: 2
• Pages: 329-340
• Publication date: 2025-05-20
• Acceptance date: 2025-05-12
• DOI: 10.1007/s11060-025-05082-1
• EISSN: 1573-7373
• ISSN: 0167-594X
• Language: English
• Keywords: Hormonal therapy; Meningioma; PI3K-AKT-mTOR pathway; Progestins; PIK3CA mutation
• Subtype: Review